Abstract: The present invention relates to an immunogenic composition comprising: a) one or more antigen of M. hyorhinis and one or more antigens of M. hyosynoviae; and b) a pharmaceutically acceptable carrier. Furthermore, the present invention relates to an immunogenic composition that comprises a) one or more mycoplasma antigens of mycoplasma bacteria selected from the group consisting of M. hyorhinis, M. hyopneumoniae and M. hyosynoviae; and b) one or more components of a eukaryotic cell system. Moreover, the present invention also provides an immunogenic composition obtained by a method comprising a) cultivation of a mycoplasma bacteria selected from the group consisting of M. hyorhinis, M. hyopneumoniae and M. hyosynoviae in a serum-reduced, eukaryotic cell system; b) obtaining an antigen of such mycoplasma bacteria; and c) addition of a pharmaceutically acceptable carrier.

Abstract: The present invention relates to a method for the preparation of an immunogenic composition for the treatment and/or prophylaxis of mycoplasma infections in a subject comprising the cultivation of mycoplasma bacteria in a serum-reduced or swine serum-free, eukaryotic cell system; obtaining an antigen of the mycoplasma bacteria; and addition of a pharmaceutically acceptable carrier. Further, the present invention relates to the immunogenic composition obtainable by said method and a method for immunizing a subject comprising the administration of said immunogenic composition to a subject.

Abstract: The present invention relates to an immunogenic composition comprising: a) one or more antigen of M. hyorhinis and one or more antigens of M. hyosynoviae; and b) a pharmaceutically acceptable carrier. Furthermore, the present invention relates to an immunogenic composition that comprises a) one or more mycoplasma antigens of mycoplasma bacteria selected from the group consisting of M. hyorhinis, M. hyopneumoniae and M. hyosynoviae; and b) one or more components of a eukaryotic cell system. Moreover, the present invention also provides an immunogenic composition obtained by a method comprising a) cultivation of a mycoplasma bacteria selected from the group consisting of M. hyorhinis, M. hyopneumoniae and M. hyosynoviae in a serum-reduced, eukaryotic cell system; b) obtaining an antigen of such mycoplasma bacteria; and c) addition of a pharmaceutically acceptable carrier.

Abstract: The present invention relates to an immunogenic composition comprising: a) one or more antigen of M. hyorhinis and one or more antigens of M. hyosynoviae; and b) a pharmaceutically acceptable carrier. Furthermore, the present invention relates to an immunogenic composition that comprises a) one or more mycoplasma antigens of mycoplasma bacteria selected from the group consisting of M. hyorhinis, M. hyopneumoniae and M. hyosynoviae; and b) one or more components of a eukaryotic cell system. Moreover, the present invention also provides an immunogenic composition obtained by a method comprising a) cultivation of a mycoplasma bacteria selected from the group consisting of M. hyorhinis, M. hyopneumoniae and M. hyosynoviae in a serum-reduced, eukaryotic cell system; b) obtaining an antigen of such mycoplasma bacteria; and c) addition of a pharmaceutically acceptable carrier.

Abstract: The present invention relates to Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) mutant strains having increased stability; compositions containing the strains or antigens derived therefrom; vaccines containing the strains, including killed, attenuated or subunit vaccines; nucleic acids encoding PRRSV polypeptides, polypeptides encoded by the nucleic acids, including antigenic fragments thereof; antibodies which specifically bind to said polypeptides, and methods making and using thereof.

Abstract: The present invention relates to a method for the preparation of an immunogenic composition for the treatment and/or prophylaxis of mycoplasma infections in a subject comprising the cultivation of mycoplasma bacteria in a serum-reduced or swine serum-free, eukaryotic cell system; obtaining an antigen of the mycoplasma bacteria; and addition of a pharmaceutically acceptable carrier. Further, the present invention relates to the immunogenic composition obtainable by said method and a method for immunizing a subject comprising the administration of said immunogenic composition to a subject.

Abstract: The present invention relates to a method for the preparation of an immunogenic composition for the treatment and/or prophylaxis of mycoplasma infections in a subject comprising the cultivation of mycoplasma bacteria in a serum-reduced or swine serum-free, eukaryotic cell system; obtaining an antigen of the mycoplasma bacteria; and addition of a pharmaceutically acceptable carrier. Further, the present invention relates to the immunogenic composition obtainable by said method and a method for immunizing a subject comprising the administration of said immunogenic composition to a subject.

Abstract: A pre-paid service system configured to provide a subscriber interface to a Subscriber and receive a service level selection from the subscriber, wherein the service level selection includes a capacity limit and/or a time limit. Upon authorization of a payment, the system activates the Subscriber's service. The system also monitors the Subscriber's usage data and time of activation. When the Subscriber's usage data amount or time of activation meets or exceeds the selected service level, the system may deactivate the Subscriber's service.

Abstract: The present invention relates to Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) mutant strains having increased stability; compositions containing the strains or antigens derived therefrom; vaccines containing the strains, including killed, attenuated or subunit vaccines; nucleic acids encoding PRRSV polypeptides, polypeptides encoded by the nucleic acids, including antigenic fragments thereof; antibodies which specifically bind to said polypeptides, and methods making and using thereof.

Abstract: The present invention relates to a method for the preparation of an immunogenic composition for the treatment and/or prophylaxis of mycoplasma infections in a subject comprising the cultivation of mycoplasma bacteria in a serum-reduced or swine serum-free, eukaryotic cell system; obtaining an antigen of the mycoplasma bacteria; and addition of a pharmaceutically acceptable carrier. Further, the present invention relates to the immunogenic composition obtainable by said method and a method for immunizing a subject comprising the administration of said immunogenic composition to a subject.

Abstract: The present invention relates to an immunogenic composition comprising: a) one or more antigen of M. hyorhinis and one or more antigens of M. hyosynoviae; and b) a pharmaceutically acceptable carrier. Furthermore, the present invention relates to an immunogenic composition that comprises a) one or more mycoplasma antigens of mycoplasma bacteria selected from the group consisting of M. hyorhinis, M. hyopneumoniae and M. hyosynoviae; and b) one or more components of a eukaryotic cell system. Moreover, the present invention also provides an immunogenic composition obtained by a method comprising a) cultivation of a mycoplasma bacteria selected from the group consisting of M. hyorhinis, M. hyopneumoniae and M. hyosynoviae in a serum-reduced, eukaryotic cell system; b) obtaining an antigen of such mycoplasma bacteria; and c) addition of a pharmaceutically acceptable carrier.

Abstract: A pre-paid service system configured to provide a subscriber interface to a Subscriber and receive a service level selection from the subscriber, wherein the service level selection includes a capacity limit and/or a time limit. Upon authorization of a payment, the system activates the Subscriber's service. The system also monitors the Subscriber's usage data and time of activation. When the Subscriber's usage data amount or time of activation meets or exceeds the selected service level, the system may deactivate the Subscriber's service.

Abstract: Several nodes are connected to a ring structure by means of communication lines in a network for packet-oriented data traffic. Each node is connected to lines of the ring structure. A buffer circuit is provided between the high speed interfaces for reading a routing information on the head of a data packet. The buffer circuits are structured in such a manner that the delay time in the transit traffic is smaller than, for example, 10 .mu.s. Several users are connected at the node. A wait line circuit is provided for each user. A controller ensures the processing of the data packets in the transit, insert and extract modes.

Abstract: In digital data packets comprising a first datum from which a second datum can be unequivocally computed, e.g. an error correction value, one or a plurality of additional data can be introduced by manipulating said second datum without altering the structure of the data packet. For this purpose, one or a plurality of bits of the second datum are modified in an unequivocally reversible manner, e.g. inverted, according to the additional datum which is also digital. The recuperation of the additional data is effected by comparing comparative values which are obtained by reversing all possible combinations of additional data in a received data packet to a value which is computed from the first datum of the data packet: The presence of the corresponding combination of additional data results from the consistency of the latter with one of said comparative values. Another possibility is to limit the inquiry to a fraction of the possible combination.

Abstract: The code word recognition unit (51) comprises an optical switching element which can be controlled electrically and serves as a light switch, a sequence generator (75) for electrically controlling the switching element (57), an optoelectrical transducer (60), an electrical integrator (63), a threshold circuit (66) and a control unit (69). In addition, there is a clock generator (72) and a decision unit (73).Code words appear periodically at the input (53) as optical bit patterns (OM) which are synchronized with an assigned electrical comparison pattern (VM) at the control input (44). The light let through by the switching element (57) forms a voltage pulse (U) via the transducer (60) at the integrator (63), the level of the voltage pulse (U) forming a measurement for the agreement of the two patterns (OM, VM). If the two patterns agree, there is a clear maximum.The code word recognition unit (51) serves for the rapid recognition of address codes on optical lines.

Abstract: The transmission equipment includes a plurality of subscriber nodes which are connected serially to an optical fiber. Every node comprises an access unit with at least one directional coupler, an address detection unit, a receiver, a synchronization unit, as well as a control unit with a switching transmitter. Addressed packets continuously reach the nodes and pass through the latter via the fiber in the form of modulated light. In a first switching position, the directional coupler branches off a part of the light power of the packets from the fiber, converts the light in the optoelectrical transducer into electrical signals and reads the respective packet address in the detection unit. If this packet address matches the address of the node the control unit switches the directional coupler into a second switching position. The coupler branches off another part of the light power of the packet in this second switching position and, in so doing, feeds the occurring electrical useful signals to the receiver.

Abstract: The bit and frame synchronization unit (51) serves for the synchronization of an access node to the bit stream running along an optical fiber.The unit (51) comprises an optical switching element (57) which can be controlled electrically and serves as a light switch. It further comprises a sequence generator (75) for electrically controlling the switching element (57), a clock generator (72), an optoelectrical transducer (60), an electrical integrator (63), a regulator and evaluator (66) and a control unit (69). In addition, there is a coarse regulator (48).An optical bit pattern (BM) occurs periodically at the input (53), an equivalent electrical comparison pattern (VM) assigned to the latter occurs at the control input (44). The level of the resultant electrical voltage pulse U at the output (64) of the integrator (63) is a measurement for the respective relative phase deviation during approximate synchronous running. There is a sharp pulse maximum during absolute synchronous running.